# Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects

> **NCT06528665** · — · COMPLETED · sponsor: **Corium Innovations, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis
- Ulcerative Colitis

## Interventions

- **DRUG:** ZEPOSIA® indicated for the treatment of: Relapsing forms of multiple sclerosis, and active ulcerative colitis in adults

## Key facts

- **NCT ID:** NCT06528665
- **Lead sponsor:** Corium Innovations, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-10
- **Primary completion:** 2025-03-16
- **Final completion:** 2025-04-16
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528665, "Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06528665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*